Symbols / OCS Stock $26.77 -3.88% Oculis Holding AG
OCS (Stock) Chart
About
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Stock Fundamentals
Scroll to Statements| Market Cap | 1.55B | Enterprise Value | 1.34B | Income | -98.96M | Sales | 1.20M | Book/sh | 4.32 | Cash/sh | 3.67 |
| Dividend Yield | — | Payout | — | Employees | 60 | IPO | — | P/E | — | Forward P/E | -12.37 |
| PEG | — | P/S | 1294.62 | P/B | 6.20 | P/C | — | EV/EBITDA | -16.46 | EV/Sales | 1118.88 |
| Quick Ratio | 5.85 | Current Ratio | 5.96 | Debt/Eq | 1.18 | LT Debt/Eq | — | EPS (ttm) | -2.42 | EPS next Y | -2.16 |
| EPS Growth | — | Revenue Growth | 136.00% | Earnings | 2026-05-11 | ROA | -28.65% | ROE | -73.45% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | -50.20% | Profit Margin | 0.00% | Shs Outstand | 57.98M | Shs Float | 49.91M | Short Float | 0.95% |
| Short Ratio | 1.29 | Short Interest | — | 52W High | 30.68 | 52W Low | 16.00 | Beta | 0.21 | Avg Volume | 341.21K |
| Volume | 415.01K | Target Price | $47.57 | Recom | Strong_buy | Prev Close | $27.85 | Price | $26.77 | Change | -3.88% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$47.57
Mean price target
2. Current target
$26.77
Latest analyst target
3. DCF / Fair value
$-13.56
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$26.77
Low
$37.84
High
$56.05
Mean
$47.57
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-20 | reit | HC Wainwright & Co. | Buy → Buy | $44 |
| 2026-03-05 | main | Stifel | Buy → Buy | $50 |
| 2026-03-04 | main | HC Wainwright & Co. | Buy → Buy | $44 |
| 2026-03-04 | main | Needham | Buy → Buy | $40 |
| 2025-12-19 | main | Stifel | Buy → Buy | $40 |
| 2025-12-19 | init | JP Morgan | — → Overweight | $38 |
| 2025-12-03 | init | LifeSci Capital | — → Outperform | $55 |
| 2025-11-13 | main | B of A Securities | Buy → Buy | $29 |
| 2025-11-11 | main | Chardan Capital | Buy → Buy | $51 |
| 2025-11-11 | main | HC Wainwright & Co. | Buy → Buy | $42 |
| 2025-11-11 | reit | Needham | Buy → Buy | $36 |
| 2025-10-08 | main | Chardan Capital | Buy → Buy | $51 |
| 2025-10-07 | main | HC Wainwright & Co. | Buy → Buy | $36 |
| 2025-08-27 | init | Needham | — → Buy | $36 |
| 2025-08-22 | main | HC Wainwright & Co. | Buy → Buy | $33 |
| 2025-05-09 | main | Chardan Capital | Buy → Buy | $33 |
| 2025-04-17 | main | Chardan Capital | Buy → Buy | $28 |
| 2025-04-17 | main | HC Wainwright & Co. | Buy → Buy | $32 |
| 2025-03-13 | main | Chardan Capital | Buy → Buy | $28 |
| 2025-03-13 | main | Baird | Outperform → Outperform | $41 |
News
RSS: Latest OCS news- Oculis shareholders get May 11 briefing ahead of May 13 AGM - Stock Titan ue, 21 Apr 2026 20
- Oculis Completes Last Patient Visits in Phase 3 DIAMOND Trials for OCS-01, Anticipates Topline Results in June 2026 - Quiver Quantitative Mon, 20 Apr 2026 08
- Why Oculis Holding (OCS) Is Up 5.5% After Phase 3 DME Trial Milestone – And What's Next - simplywall.st ue, 21 Apr 2026 05
- OCS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $44 - GuruFocus Mon, 20 Apr 2026 20
- Lumentum's OCS and CPO Momentum Builds: More Upside for the Stock? - Yahoo Finance ue, 24 Feb 2026 08
- Oculis Sets May 13, 2026 AGM in Zug and Schedules Shareholder Info Session - TipRanks ue, 21 Apr 2026 20
- 800+ patients finish Oculis diabetic eye-drop trials before June data - Stock Titan Mon, 20 Apr 2026 08
- Can Oculis (OCS) Stock Recover Now | Price at $27.39, Up 0.74% - Community Buy Signals - Cổng thông tin điện tử Tỉnh Sơn La Fri, 10 Apr 2026 07
- OCS Options Chain — NASDAQ:OCS - TradingView Sat, 11 Apr 2026 07
- H.C. Wainwright reiterates Oculis stock rating on trial completion By Investing.com - Investing.com Canada ue, 21 Apr 2026 11
- Liquidity Mapping Around (OCS) Price Events - Stock Traders Daily ue, 14 Apr 2026 09
- Oculis Holding (NasdaqGM:OCS) Valuation Check After Strong Three Year Gains And Recent Share Price Pullback - Yahoo Finance Sun, 08 Mar 2026 08
- OCS Options Volatility — NASDAQ:OCS - TradingView Sat, 11 Apr 2026 08
- Oculis (Nasdaq: OCS) sets 2026 AGM, details late-stage pipeline and expanded share capital tools - Stock Titan ue, 21 Apr 2026 20
- OCULIS HOLDING ($OCS) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative ue, 03 Mar 2026 08
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
81.67
+11.57%
|
73.20
+59.66%
|
45.85
+41.62%
|
32.38
|
| Research And Development |
|
57.09
+9.60%
|
52.08
+78.08%
|
29.25
+31.60%
|
22.22
|
| Selling General And Administration |
|
23.20
+22.60%
|
18.92
+28.50%
|
14.72
+118.36%
|
6.74
|
| General And Administrative Expense |
|
23.20
+22.60%
|
18.92
+28.50%
|
14.72
+118.36%
|
6.74
|
| Salaries And Wages |
|
15.00
+30.68%
|
11.48
+63.27%
|
7.03
+57.99%
|
4.45
|
| Other Gand A |
|
8.20
+10.14%
|
7.45
-3.25%
|
7.70
+235.44%
|
2.29
|
| Other Operating Expenses |
|
1.19
-42.56%
|
2.06
+13.54%
|
1.82
-45.55%
|
3.34
|
| Total Expenses |
|
81.67
+11.57%
|
73.20
+59.66%
|
45.85
+41.62%
|
32.38
|
| Operating Income |
|
-81.67
-11.57%
|
-73.20
-59.66%
|
-45.85
-41.62%
|
-32.38
|
| Total Operating Income As Reported |
|
-81.67
-11.57%
|
-73.20
+9.30%
|
-80.71
-149.30%
|
-32.38
|
| EBITDA |
|
-97.76
-15.16%
|
-84.89
+2.53%
|
-87.09
-173.00%
|
-31.90
|
| Normalized EBITDA |
|
-79.36
-12.35%
|
-70.63
-60.03%
|
-44.13
-38.13%
|
-31.95
|
| Reconciled Depreciation |
|
0.55
+34.48%
|
0.41
+41.46%
|
0.29
-4.01%
|
0.30
|
| EBIT |
|
-98.31
-15.25%
|
-85.30
+2.38%
|
-87.38
-171.36%
|
-32.20
|
| Total Unusual Items |
|
-18.41
-29.07%
|
-14.26
+66.80%
|
-42.96
-87769.39%
|
0.05
|
| Total Unusual Items Excluding Goodwill |
|
-18.41
-29.07%
|
-14.26
+66.80%
|
-42.96
-87769.39%
|
0.05
|
| Special Income Charges |
|
0.00
|
0.00
+100.00%
|
-34.86
|
0.00
|
| Restructuring And Mergern Acquisition |
|
0.00
|
0.00
-100.00%
|
34.86
|
0.00
|
| Net Income |
|
-98.96
-15.37%
|
-85.78
+3.41%
|
-88.80
-129.47%
|
-38.70
|
| Pretax Income |
|
-99.14
-15.37%
|
-85.94
+3.11%
|
-88.69
-129.52%
|
-38.64
|
| Net Non Operating Interest Income Expense |
|
0.94
-38.72%
|
1.53
+1241.23%
|
0.11
+101.80%
|
-6.32
|
| Interest Expense Non Operating |
|
0.83
+30.36%
|
0.64
-51.41%
|
1.31
-79.59%
|
6.44
|
| Net Interest Income |
|
0.94
-38.72%
|
1.53
+1241.23%
|
0.11
+101.80%
|
-6.32
|
| Interest Expense |
|
0.83
+30.36%
|
0.64
-51.41%
|
1.31
-79.59%
|
6.44
|
| Interest Income Non Operating |
|
1.77
-18.36%
|
2.17
+51.71%
|
1.43
+1034.13%
|
0.13
|
| Interest Income |
|
1.77
-18.36%
|
2.17
+51.71%
|
1.43
+1034.13%
|
0.13
|
| Other Income Expense |
|
-18.41
-29.07%
|
-14.26
+66.80%
|
-42.96
-87769.39%
|
0.05
|
| Gain On Sale Of Security |
|
-18.41
-29.07%
|
-14.26
-76.18%
|
-8.10
-16620.41%
|
0.05
|
| Tax Provision |
|
-0.19
-16.25%
|
-0.16
-249.53%
|
0.11
+94.55%
|
0.06
|
| Tax Rate For Calcs |
|
0.00
+0.75%
|
0.00
-97.81%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.03
-30.06%
|
-0.03
+99.27%
|
-3.65
-87769.39%
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-98.96
-15.37%
|
-85.78
+3.41%
|
-88.80
-129.47%
|
-38.70
|
| Net Income From Continuing Operation Net Minority Interest |
|
-98.96
-15.37%
|
-85.78
+3.41%
|
-88.80
-129.47%
|
-38.70
|
| Net Income From Continuing And Discontinued Operation |
|
-98.96
-15.37%
|
-85.78
+3.41%
|
-88.80
-129.47%
|
-38.70
|
| Net Income Continuous Operations |
|
-98.96
-15.37%
|
-85.78
+3.41%
|
-88.80
-129.47%
|
-38.70
|
| Normalized Income |
|
-80.58
-12.64%
|
-71.54
-44.54%
|
-49.50
-27.75%
|
-38.74
|
| Net Income Common Stockholders |
|
-98.96
-15.37%
|
-85.78
+3.41%
|
-88.80
-129.47%
|
-38.70
|
| Diluted EPS |
|
-1.89
+10.85%
|
-2.12
+28.62%
|
-2.97
+73.76%
|
-11.32
|
| Basic EPS |
|
-1.89
+10.85%
|
-2.12
+28.62%
|
-2.97
+73.76%
|
-11.32
|
| Basic Average Shares |
|
52.36
+29.58%
|
40.41
+35.14%
|
29.90
-8.66%
|
32.73
|
| Diluted Average Shares |
|
52.36
+29.58%
|
40.41
+35.14%
|
29.90
-8.66%
|
32.73
|
| Diluted NI Availto Com Stockholders |
|
-98.96
-15.37%
|
-85.78
+3.41%
|
-88.80
-129.47%
|
-38.70
|
| Depreciation Amortization Depletion Income Statement |
|
0.20
+49.64%
|
0.14
+117.46%
|
0.06
-12.50%
|
0.07
|
| Depreciation And Amortization In Income Statement |
|
0.20
+49.64%
|
0.14
+117.46%
|
0.06
-12.50%
|
0.07
|
| Depreciation Income Statement |
|
0.20
+49.64%
|
0.14
+117.46%
|
0.06
-12.50%
|
0.07
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Assets |
|
235.96
+96.06%
|
120.35
|
| Current Assets |
|
218.89
+108.67%
|
104.90
|
| Cash Cash Equivalents And Short Term Investments |
|
213.01
+115.90%
|
98.66
|
| Cash And Cash Equivalents |
|
81.33
+193.52%
|
27.71
|
| Cash Equivalents |
|
—
|
12.47
|
| Cash Financial |
|
—
|
15.23
|
| Other Short Term Investments |
|
131.68
+85.59%
|
70.95
|
| Receivables |
|
1.79
+18.49%
|
1.51
|
| Other Receivables |
|
0.99
+57.87%
|
0.63
|
| Taxes Receivable |
|
0.80
-9.49%
|
0.89
|
| Prepaid Assets |
|
4.08
-13.52%
|
4.72
|
| Total Non Current Assets |
|
17.07
+10.47%
|
15.46
|
| Net PPE |
|
3.00
+77.55%
|
1.69
|
| Gross PPE |
|
3.90
+56.03%
|
2.50
|
| Accumulated Depreciation |
|
-0.90
-11.12%
|
-0.81
|
| Properties |
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.55
+18.38%
|
0.47
|
| Other Properties |
|
3.16
+63.85%
|
1.93
|
| Leases |
|
0.18
+81.63%
|
0.10
|
| Goodwill And Other Intangible Assets |
|
13.29
+0.00%
|
13.29
|
| Other Intangible Assets |
|
13.29
+0.00%
|
13.29
|
| Investments And Advances |
|
—
|
—
|
| Non Current Deferred Assets |
|
—
|
—
|
| Non Current Deferred Taxes Assets |
|
—
|
—
|
| Other Non Current Assets |
|
0.79
+64.92%
|
0.48
|
| Total Liabilities Net Minority Interest |
|
39.89
-15.07%
|
46.97
|
| Current Liabilities |
|
36.75
-16.93%
|
44.23
|
| Payables And Accrued Expenses |
|
17.28
-15.20%
|
20.37
|
| Payables |
|
2.73
-53.82%
|
5.92
|
| Accounts Payable |
|
1.80
-69.34%
|
5.87
|
| Other Payable |
|
0.94
+1733.33%
|
0.05
|
| Current Accrued Expenses |
|
14.54
+0.62%
|
14.45
|
| Employee Benefits |
|
1.33
-28.61%
|
1.87
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
4.49
+21.51%
|
3.70
|
| Current Debt And Capital Lease Obligation |
|
0.50
+59.37%
|
0.32
|
| Current Capital Lease Obligation |
|
0.50
+59.37%
|
0.32
|
| Other Current Liabilities |
|
14.48
-27.07%
|
19.85
|
| Total Non Current Liabilities Net Minority Interest |
|
3.15
+15.03%
|
2.73
|
| Long Term Debt And Capital Lease Obligation |
|
1.81
+109.36%
|
0.86
|
| Long Term Debt |
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
1.81
+109.36%
|
0.86
|
| Non Current Pension And Other Postretirement Benefit Plans |
|
1.33
-28.61%
|
1.87
|
| Tradeand Other Payables Non Current |
|
—
|
0.00
|
| Non Current Deferred Liabilities |
|
—
|
—
|
| Non Current Deferred Taxes Liabilities |
|
—
|
—
|
| Other Non Current Liabilities |
|
—
|
—
|
| Stockholders Equity |
|
196.07
+167.19%
|
73.38
|
| Common Stock Equity |
|
196.07
+167.19%
|
73.38
|
| Capital Stock |
|
0.59
+31.61%
|
0.45
|
| Common Stock |
|
0.59
+31.61%
|
0.45
|
| Share Issued |
|
58.69
+31.40%
|
44.66
|
| Ordinary Shares Number |
|
57.98
+32.80%
|
43.66
|
| Treasury Shares Number |
|
0.70
-29.63%
|
1.00
|
| Additional Paid In Capital |
|
551.73
+59.95%
|
344.95
|
| Retained Earnings |
|
-384.51
-34.65%
|
-285.56
|
| Gains Losses Not Affecting Retained Earnings |
|
-2.11
+15.58%
|
-2.50
|
| Treasury Stock |
|
0.01
-30.00%
|
0.01
|
| Total Equity Gross Minority Interest |
|
196.07
+167.19%
|
73.38
|
| Total Capitalization |
|
196.07
+167.19%
|
73.38
|
| Working Capital |
|
182.14
+200.26%
|
60.66
|
| Invested Capital |
|
196.07
+167.19%
|
73.38
|
| Total Debt |
|
2.31
+96.02%
|
1.18
|
| Net Debt |
|
—
|
—
|
| Capital Lease Obligations |
|
2.31
+96.02%
|
1.18
|
| Net Tangible Assets |
|
182.78
+204.17%
|
60.09
|
| Tangible Book Value |
|
182.78
+204.17%
|
60.09
|
| Duefrom Related Parties Current |
|
—
|
—
|
| Foreign Currency Translation Adjustments |
|
-0.48
-77.12%
|
-0.27
|
| Investmentin Financial Assets |
|
—
|
—
|
| Minimum Pension Liabilities |
|
-1.63
+26.82%
|
-2.23
|
| Other Equity Interest |
|
30.39
+89.19%
|
16.06
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-66.30
-35.54%
|
-48.92
+11.12%
|
-55.04
-119.50%
|
-25.07
|
| Cash Flow From Continuing Operating Activities |
|
-66.30
-35.54%
|
-48.92
+11.12%
|
-55.04
-119.50%
|
-25.07
|
| Net Income From Continuing Operations |
|
-99.14
-15.37%
|
-85.94
+3.11%
|
-88.69
-129.52%
|
-38.64
|
| Depreciation Amortization Depletion |
|
0.55
+34.48%
|
0.41
+41.46%
|
0.29
-4.01%
|
0.30
|
| Depreciation |
|
0.55
+34.48%
|
0.41
+41.46%
|
0.29
-4.01%
|
0.30
|
| Depreciation And Amortization |
|
0.55
+34.48%
|
0.41
+41.46%
|
0.29
-4.01%
|
0.30
|
| Other Non Cash Items |
|
3.98
+248.95%
|
-2.67
-106.75%
|
39.59
+511.88%
|
6.47
|
| Pension And Employee Benefit Expense |
|
0.10
+380.56%
|
-0.04
+78.95%
|
-0.17
-1800.00%
|
-0.01
|
| Stock Based Compensation |
|
16.04
+64.02%
|
9.78
+171.12%
|
3.61
+348.76%
|
0.80
|
| Operating Gains Losses |
|
12.39
-20.01%
|
15.49
+375.31%
|
3.26
+36322.22%
|
-0.01
|
| Gain Loss On Investment Securities |
|
12.29
-20.84%
|
15.53
+352.67%
|
3.43
|
—
|
| Net Foreign Currency Exchange Gain Loss |
|
—
|
—
|
-0.03
-105.15%
|
0.58
|
| Change In Working Capital |
|
-0.07
-100.52%
|
14.16
+209.01%
|
-12.99
-316.59%
|
6.00
|
| Change In Receivables |
|
-0.36
-247.37%
|
0.25
+586.11%
|
0.04
+123.68%
|
-0.15
|
| Change In Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Change In Payables And Accrued Expense |
|
-1.95
-121.57%
|
9.03
+221.31%
|
-7.44
-193.66%
|
7.95
|
| Change In Accrued Expense |
|
—
|
11.11
+196.23%
|
-11.55
-335.55%
|
4.90
|
| Change In Payable |
|
-1.95
-121.57%
|
9.03
+221.31%
|
-7.44
-344.56%
|
3.04
|
| Change In Account Payable |
|
-1.95
-120.70%
|
9.41
+220.28%
|
-7.82
-356.98%
|
3.04
|
| Change In Other Working Capital |
|
-0.11
-17.89%
|
-0.10
-227.59%
|
-0.03
|
—
|
| Change In Other Current Assets |
|
2.35
-52.84%
|
4.98
+189.65%
|
-5.56
-209.35%
|
-1.80
|
| Investing Cash Flow |
|
-60.93
-278.87%
|
-16.08
+69.64%
|
-52.97
-1393.04%
|
-3.55
|
| Cash Flow From Continuing Investing Activities |
|
-60.93
-278.87%
|
-16.08
+69.64%
|
-52.97
-1393.04%
|
-3.55
|
| Net PPE Purchase And Sale |
|
-0.30
-30.87%
|
-0.23
-379.17%
|
-0.05
+26.15%
|
-0.07
|
| Purchase Of PPE |
|
-0.30
-30.87%
|
-0.23
-379.17%
|
-0.05
+26.15%
|
-0.07
|
| Capital Expenditure |
|
-1.39
-503.48%
|
-0.23
-379.17%
|
-0.05
+98.65%
|
-3.55
|
| Net Investment Purchase And Sale |
|
-60.79
-250.82%
|
-17.33
+68.01%
|
-54.16
|
0.00
|
| Purchase Of Investment |
|
-60.79
-250.82%
|
-17.33
+68.01%
|
-54.16
|
0.00
|
| Net Intangibles Purchase And Sale |
|
-1.09
|
0.00
|
0.00
+100.00%
|
-3.48
|
| Purchase Of Intangibles |
|
-1.09
|
0.00
|
0.00
+100.00%
|
-3.48
|
| Financing Cash Flow |
|
186.92
+246.30%
|
53.98
-58.36%
|
129.63
+7462.78%
|
1.71
|
| Cash Flow From Continuing Financing Activities |
|
186.92
+246.30%
|
53.98
-58.36%
|
129.63
+7462.78%
|
1.71
|
| Net Issuance Payments Of Debt |
|
-0.37
-36.13%
|
-0.27
-73.42%
|
-0.16
+0.63%
|
-0.16
|
| Repayment Of Debt |
|
-0.37
-36.13%
|
-0.27
-73.42%
|
-0.16
+0.63%
|
-0.16
|
| Long Term Debt Payments |
|
-0.37
-36.13%
|
-0.27
-73.42%
|
-0.16
+0.63%
|
-0.16
|
| Net Long Term Debt Issuance |
|
-0.37
-36.13%
|
-0.27
-73.42%
|
-0.16
+0.63%
|
-0.16
|
| Net Common Stock Issuance |
|
178.86
+234.06%
|
53.54
-60.52%
|
135.62
|
0.00
|
| Cash Dividends Paid |
|
0.00
|
0.00
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
21.74
+494.50%
|
3.66
+102.60%
|
1.80
+1404.17%
|
0.12
|
| Net Other Financing Charges |
|
-13.22
-356.88%
|
-2.89
+61.87%
|
-7.59
-2640.07%
|
-0.28
|
| Changes In Cash |
|
59.68
+641.27%
|
-11.03
-151.01%
|
21.62
+180.33%
|
-26.91
|
| Effect Of Exchange Rate Changes |
|
-6.06
-1588.70%
|
0.41
+113.24%
|
-3.08
-835.65%
|
0.42
|
| Beginning Cash Position |
|
27.71
-27.71%
|
38.33
+93.71%
|
19.79
-57.24%
|
46.28
|
| End Cash Position |
|
81.33
+193.52%
|
27.71
-27.71%
|
38.33
+93.71%
|
19.79
|
| Free Cash Flow |
|
-67.69
-37.73%
|
-49.15
+10.78%
|
-55.09
-92.46%
|
-28.62
|
| Common Stock Issuance |
|
178.86
+234.06%
|
53.54
-60.52%
|
135.62
|
0.00
|
| Interest Paid CFF |
|
-0.09
-61.11%
|
-0.05
-17.39%
|
-0.05
|
—
|
| Interest Paid CFO |
|
—
|
-0.05
-17.39%
|
-0.05
+54.00%
|
-0.10
|
| Interest Received CFI |
|
1.24
-15.81%
|
1.47
+19.06%
|
1.24
|
—
|
| Interest Received CFO |
|
—
|
1.47
+19.06%
|
1.24
+882.54%
|
0.13
|
| Issuance Of Capital Stock |
|
178.86
+234.06%
|
53.54
-60.52%
|
135.62
+6580.54%
|
2.03
|
| Net Preferred Stock Issuance |
|
—
|
0.00
|
0.00
-100.00%
|
2.03
|
| Preferred Stock Issuance |
|
—
|
0.00
|
0.00
-100.00%
|
2.03
|
| Taxes Refund Paid |
|
-0.06
+63.82%
|
-0.15
-50.50%
|
-0.10
-405.00%
|
-0.02
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|